Categories: News

VALNEVA – Declaration of shares and voting rights – March 31, 2023

VALNEVA

Declaration of shares and voting rights
March 31, 2023
__________________________________________________________________________________________

Company name: VALNEVA
Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)
Regulated market of Euronext Paris – Compartment B

Declaration date: April 6, 2023

Number of shares
composing the share capital of Valneva
Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights**
 

138,346,968

ordinary shares with a par value of €0.15 each


160,955,498 Double voting rights granted on 230 ordinary shares

 

Sale of 50 shares with double voting rights

Between March 3 & March 15, 2023

 

March 29, 2023

160,831,176

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
** Net (or exercisable at a General Meeting) voting rights.

Attachment

Staff

Recent Posts

For Pride Month, Mental Health Professionals Offer Parenting Help

Parenting is a hard job under the best of circumstances. It can be especially confusing…

1 hour ago

Curiteva Announces the Beginning of the Commercial Launch of the Inspire(R) Posterior Interbody Solutions

HUNTSVILLE, AL / ACCESSWIRE / June 19, 2024 / Curiteva, Inc., a leading technology and…

1 hour ago

Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically

TORONTO, ON / ACCESSWIRE / June 19, 2024 / Theralase® Technologies Inc. ("Theralase®" or the…

1 hour ago

Sharecare announces inducement grants under Nasdaq Listing Rule 5635(c)(4)

ATLANTA, June 19, 2024 (GLOBE NEWSWIRE) -- Sharecare (NASDAQ: SHCR), the digital health company that…

1 hour ago

Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people…

1 hour ago

Calibre Scientific Acquires DCS, a German Provider of Antibodies, Reagents and Equipment Used in Immunohistochemistry

LOS ANGELES, June 19, 2024 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the…

1 hour ago